Gwen M Allen, MD
Obstetrics/Gynecology · Gardena
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 32 years
- University of California, Geffen School of Medicine, 1994
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Allen’s office at (310) 329-9492 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$11,780
Medicare paid this office $11,780 for 44 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 32 | $8,924 | $96 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
44 Original Medicare patients in 2024. Average age 65 · Women 100% · Health risk score 1.36. Sicker patients than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 75% · Diabetes 43% · Chronic kidney disease 25%.
The office billed $48,448, Medicare allowed $16,323 and paid $11,780; for 133 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 44 | 133 | 65 | 1.36 | $48,448 | $11,780 |
| 2023 | 111 | 418 | 63 | 1.81 | $148,367 | $43,112 |
| 2022 | 79 | 178 | 64 | 1.53 | $51,418 | $16,514 |
| 2020 | 75 | 1,056 | 61 | 1.64 | $32,731 | $11,055 |
| 2019 | 98 | 516 | 63 | 1.79 | $53,501 | $20,124 |
| 2018 | 79 | 180 | 61 | 1.79 | $45,872 | $16,348 |
| 2017 | 90 | 203 | 57 | 1.84 | $44,941 | $16,392 |
| 2016 | 79 | 154 | 57 | 1.87 | $30,214 | $12,748 |
| 2015 | 54 | 152 | 57 | 1.64 | $22,230 | $12,207 |
| 2014 | 69 | 175 | 60 | 1.78 | $32,090 | $13,165 |
| 2013 | 73 | 156 | 54 | 1.44 | $37,500 | $17,075 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 46 | $11,277 | $103 |
| Short return visit (20+ min) | 58 | $9,784 | $72 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 43 | $2,096 | $49 |
| New patient visit (45+ min) | 17 | $2,002 | $118 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $1,886 | $43 |
2022: 3 services
| Short return visit (20+ min) | 46 | $6,758 | $80 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 24 | $1,044 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 17 | $831 | $49 |
2020: 3 services
| Short return visit (20+ min) | 44 | $4,255 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 17 | $753 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $634 | $49 |
2019: 5 services
| Short return visit (20+ min) | 41 | $5,392 | $62 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 12 | $2,247 | $187 |
| New patient visit (30+ min) | 22 | $1,896 | $86 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 22 | $1,072 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $899 | $43 |
2018: 2 services
| Short return visit (20+ min) | 40 | $5,618 | $57 |
| New patient visit (30+ min) | 14 | $1,095 | $78 |
2017: 2 services
| Short return visit (20+ min) | 51 | $6,556 | $55 |
| New patient visit (30+ min) | 17 | $1,285 | $76 |
2016: 3 services
| Short return visit (20+ min) | 37 | $4,206 | $57 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 20 | $978 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $859 | $41 |
2015: 3 services
| Short return visit (20+ min) | 29 | $2,854 | $56 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $650 | $50 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | $502 | $42 |
2014: 3 services
| Short return visit (20+ min) | 40 | $4,548 | $59 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 21 | $1,027 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | $940 | $41 |
2013: 3 services
| Short return visit (20+ min) | 41 | $5,520 | $56 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 13 | $2,362 | $182 |
| New patient visit (30+ min) | 13 | $1,078 | $83 |
Medicaid work
$85,423 in 2024
Medicaid paid $85,423 for 4,865 billed services this clinician did in 2024, up to 223 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,164 | $24,448 |
| Prenatal care, at-risk enhanced service; antepartum management | 752 | $21,331 |
| OBSTETRICAL CARE | 63 | $17,672 |
| New patient visit (45+ min) | 197 | $6,556 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 273 | $6,400 |
| Cesarean delivery | 12 | $2,950 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 49 | $2,540 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 1,056 | $1,738 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 1,026 | $967 |
| URINE PREGNANCY TEST | 215 | $419 |
| Short return visit (20+ min) | 30 | $402 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 14 | $0 |
| 2024 | 4,865 | 13 | 223 | $85,423 |
| 2023 | 9,484 | 15 | 222 | $277,864 |
| 2022 | 4,573 | 12 | 158 | $140,034 |
| 2021 | 4,152 | 15 | 126 | $77,247 |
| 2020 | 7,494 | 15 | 121 | $235,681 |
| 2019 | 8,754 | 15 | 174 | $212,057 |
| 2018 | 7,023 | 11 | 157 | $81,849 |
See the largest Medicaid services in earlier years
2023
| OBSTETRICAL CARE | 292 | $99,933 |
| Cesarean delivery | 126 | $39,846 |
| Return visit (30+ min) | 1,698 | $33,909 |
| Short return visit (20+ min) | 2,086 | $31,364 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 892 | $25,480 |
| Prenatal care, at-risk enhanced service; antepartum management | 720 | $21,098 |
| New patient visit (45+ min) | 470 | $18,098 |
| Service | 67 | $3,696 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 2,189 | $2,929 |
| URINE PREGNANCY TEST | 563 | $1,372 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 16 | $135 |
| Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps) | 12 | $6 |
2022
| OBSTETRICAL CARE | 142 | $55,451 |
| Short return visit (20+ min) | 1,312 | $20,563 |
| Prenatal care, at-risk enhanced service; antepartum management | 554 | $19,087 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 389 | $14,035 |
| Cesarean delivery | 30 | $10,796 |
| New patient visit (45+ min) | 205 | $7,976 |
| Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | 13 | $5,561 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 1,453 | $3,164 |
| Return visit (30+ min) | 96 | $2,179 |
| URINE PREGNANCY TEST | 352 | $913 |
| Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure) | 14 | $309 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years | 13 | $0 |
2021
| OBSTETRICAL CARE | 113 | $36,640 |
| Short return visit (20+ min) | 998 | $15,405 |
| Prenatal care, at-risk enhanced service; antepartum management | 439 | $11,783 |
| New patient visit (45+ min) | 131 | $4,470 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 103 | $2,087 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 891 | $1,911 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 909 | $1,755 |
| Short return visit | 109 | $1,372 |
| Service | 21 | $1,045 |
| URINE PREGNANCY TEST | 236 | $492 |
| OFF/OP EST MAY X REQ PHY/QHP | 12 | $134 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 40 | $104 |
2020
| OBSTETRICAL CARE | 165 | $67,042 |
| Prenatal care, at-risk enhanced service; antepartum management | 1,596 | $66,799 |
| Short return visit (20+ min) | 1,335 | $29,546 |
| Short return visit | 350 | $17,615 |
| New patient visit (45+ min) | 551 | $14,847 |
| Cesarean delivery | 32 | $11,106 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 2,598 | $7,468 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 111 | $6,713 |
| Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | 17 | $4,170 |
| New patient visit (30+ min) | 187 | $3,890 |
| OFFICE/OUTPATIENT VISIT NEW | 61 | $3,169 |
| Prenatal care, at-risk assessment | 17 | $1,342 |
2019
| OBSTETRICAL CARE | 165 | $64,922 |
| Prenatal care, at-risk enhanced service; antepartum management | 677 | $26,064 |
| Short return visit | 517 | $24,419 |
| Short return visit (20+ min) | 1,361 | $19,691 |
| New patient visit (45+ min) | 686 | $17,346 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 435 | $17,099 |
| Cesarean delivery | 36 | $12,860 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 3,313 | $9,720 |
| New patient visit (30+ min) | 445 | $9,657 |
| Long return visit (40+ min) | 109 | $4,834 |
| OFFICE/OUTPATIENT VISIT NEW | 272 | $2,335 |
| New patient visit (60+ min) | 32 | $1,294 |
2018
| Short return visit | 702 | $24,990 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 690 | $19,974 |
| Short return visit (20+ min) | 1,127 | $9,408 |
| New patient visit (45+ min) | 405 | $8,266 |
| New patient visit (30+ min) | 534 | $6,563 |
| Long return visit (40+ min) | 172 | $5,898 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 2,533 | $5,857 |
| URINE PREGNANCY TEST | 467 | $543 |
| OFFICE/OUTPATIENT VISIT NEW | 354 | $227 |
| New patient visit (60+ min) | 12 | $123 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 27 | $0 |
Drugs they prescribed that Part D paid
$2,390
Pharmacies billed $2,390 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 74) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
67 generic and fewer than 11 brand-name prescriptions · $2,390 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 74 | 37 | 0% (0) | None | $2,390 |
| 2023 | 108 | 32 | 0% (0) | 19% | $6,755 |
| 2022 | 79 | 31 | 0% (0) | 25% | $4,010 |
| 2021 | 94 | 33 | None | 23% | $9,015 |
| 2020 | 69 | 27 | None | 33% | $8,086 |
| 2019 | 92 | 33 | None | 45% | $10,844 |
| 2018 | 117 | 43 | None | 22% | $13,370 |
| 2017 | 148 | 57 | None | None | $15,263 |
| 2016 | 193 | 63 | None | 15% | $12,638 |
| 2015 | 184 | 62 | None | 19% | $11,091 |
| 2014 | 176 | 69 | 6% (11) | None | $15,307 |
| 2013 | 192 | 63 | None | None | $8,614 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Estradiol | 31 | $451 | $15 |
| Medroxyprogesterone Acetate | 18 | $364 | $20 |
2022: 1 drug
| Medroxyprogesterone Acetate | 15 | $217 | $14 |
2021: 2 drugs
| Nystop | 12 | $164 | $14 |
| Medroxyprogesterone Acetate | 11 | $90 | $8 |
2020: 1 drug
| Prempro | 12 | $2,877 | $240 |
2019: 2 drugs
| Prempro | 24 | $4,636 | $193 |
| Metronidazole | 11 | $433 | $39 |
2018: 2 drugs
| Prempro | 12 | $3,014 | $251 |
| Triamcinolone Acetonide | 12 | $43 | $4 |
2017: 3 drugs
| Medroxyprogesterone Acetate | 19 | $87 | $5 |
| Fluconazole | 14 | $60 | $4 |
| Triamcinolone Acetonide | 11 | $38 | $3 |
2016: 6 drugs
| Nystop | 13 | $561 | $43 |
| Metronidazole | 12 | $480 | $40 |
| Terconazole | 12 | $385 | $32 |
| Triamcinolone Acetonide | 18 | $308 | $17 |
| Fluconazole | 30 | $146 | $5 |
| Medroxyprogesterone Acetate | 11 | $60 | $5 |
2015: 5 drugs
| Nystop | 22 | $1,245 | $57 |
| Terconazole | 19 | $621 | $33 |
| Medroxyprogesterone Acetate | 21 | $167 | $8 |
| Fluconazole | 15 | $76 | $5 |
| Triamcinolone Acetonide | 14 | $55 | $4 |
2014: 6 drugs
| Premarin | 24 | $4,836 | $202 |
| Prempro | 12 | $1,722 | $143 |
| Terconazole | 13 | $489 | $38 |
| Medroxyprogesterone Acetate | 21 | $131 | $6 |
| Triamcinolone Acetonide | 12 | $121 | $10 |
| Fluconazole | 16 | $75 | $5 |
2013: 9 drugs
| Premarin | 17 | $3,301 | $194 |
| Prempro | 13 | $1,269 | $98 |
| Nystop | 18 | $544 | $30 |
| Oxybutynin Chloride Er | 11 | $440 | $40 |
| Terconazole | 11 | $311 | $28 |
| Metronidazole | 12 | $191 | $16 |
| Triamcinolone Acetonide | 14 | $142 | $10 |
| Medroxyprogesterone Acetate | 19 | $87 | $5 |
| Fluconazole | 17 | $82 | $5 |
Money from drug and device companies
$422 in 2025
| 2025 | 10 | 19 | None | $422 |
| 2024 | 6 | 15 | None | $368 |
| 2023 | 8 | 12 | None | $575 |
| 2022 | 9 | 15 | None | $333 |
| 2021 | 7 | 13 | None | $327 |
| 2020 | 3 | 5 | None | $97 |
| 2019 | 6 | 14 | None | $274 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Myfembree | $113 | 5 payments
|
| Gilead Sciences | None | $55 | 2 payments
|
| Sage Therapeutics | Zurzuvae | $52 | 2 payments
|
| Baxter Healthcare | Perclot | $51 | 1 payment
|
| Shield Therapeutics | Accrufer | $47 | 2 payments
|
| Hologic Sales and Service | Aptima | $25 | 1 payment
|
See all 19 published payments
| Sumitomo Pharma America | Meals · 2025-12-23 | Myfembree | $22 |
| Gilead Sciences | Meals · 2025-12-18 | None | $24 |
| Sage Therapeutics | Meals · 2025-12-17 | Zurzuvae | $23 |
| Shield Therapeutics | Meals · 2025-12-10 | Accrufer | $27 |
| Becton Dickinson and | Meals · 2025-12-03 | Arista | $23 |
| Gilead Sciences | Meals · 2025-11-07 | None | $31 |
| Hologic Sales and Service | Meals · 2025-10-21 | Aptima | $25 |
| Baxter Healthcare | Meals · 2025-10-06 | Perclot | $51 |
| Sumitomo Pharma America | Meals · 2025-10-03 | Myfembree | $25 |
| Pfizer | Meals · 2025-09-05 | Abrysvo | $23 |
| Mayne Pharma Commercial | Meals · 2025-07-24 | None | $1 |
| Mayne Pharma Commercial | Meals · 2025-07-24 | None | $9 |
| Sumitomo Pharma America | Meals · 2025-06-04 | Myfembree | $26 |
| Sumitomo Pharma America | Meals · 2025-04-09 | Myfembree | $21 |
| Mayne Pharma Commercial | Meals · 2025-03-10 | None | $3 |
| Octapharma USA | Meals · 2025-03-07 | Fibryga | $20 |
| Sage Therapeutics | Meals · 2025-02-19 | Zurzuvae | $29 |
| Sumitomo Pharma America | Meals · 2025-01-22 | Myfembree | $19 |
| Shield Therapeutics | Meals · 2025-01-17 | Accrufer | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $368
| Astellas Pharma US | Veozah | $228 | 9 payments
|
| Sumitomo Pharma America | Myfembree | $41 | 2 payments
|
| Baxter Healthcare | Perclot | $32 | 1 payment
|
| Sage Therapeutics | Zurzuvae | $27 | 1 payment
|
| Mayne Pharma Commercial | None | $22 | 1 payment
|
| Smith+Nephew | Pico | $18 | 1 payment
|
2023: $575
| Applied Medical Resources | Gelpoint V-Path | $300 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $70 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $53 | 2 payments
|
| Hologic Sales and Service | Aptima | $43 | 2 payments
|
| Shield Therapeutics | Accrufer | $41 | 2 payments
|
| Exeltis USA | Slynd | $25 | 1 payment
|
| Astellas Pharma US | Veozah | $24 | 1 payment
|
| AbbVie | Lo Loestrin Fe | $19 | 1 payment
|
2022: $333
| Abbvie | Oriahnn | $90 | 4 payments
|
| Myovant Sciences | Myfembree | $58 | 3 payments
|
| Becton Dickinson and | Arista Ah Flexitip | $43 | 1 payment
|
| Exeltis USA | Nuvessa | $39 | 2 payments
|
| Ethicon US | Enseal X1 | $24 | 1 payment
|
| Organon | Jada System | $23 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $22 | 1 payment
|
| CooperSurgical | Paragard | $20 | 1 payment
|
| Hologic | Aptima | $15 | 1 payment
|
2021: $327
| AbbVie | Orilissa | $195 | 6 payments
|
| Myovant Sciences | Myfembree | $35 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $22 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $21 | 1 payment
|
| Mylan Pharmaceuticals | Xulane | $21 | 1 payment
|
| Aspira Women's Health | Ova1 | $18 | 1 payment
|
| Medicem | Dilapan-S | $16 | 1 payment
|
2020: $97
| AbbVie | Oriahnn | $62 | 3 payments
|
| Merck Sharp & Dohme | Nexplanon | $19 | 1 payment
|
| Lupin | Solosec-Ceek | $16 | 1 payment
|
2019: $274
| Merck Sharp & Dohme | Nexplanon | $91 | 5 payments
|
| AbbVie | Orilissa | $64 | 3 payments
|
| AMAG Pharmaceuticals | Intrarosa | $42 | 2 payments
|
| CooperSurgical | Paragard | $31 | 2 payments
|
| Roche Diagnostics | MD Cobas Instruments and Reagents | $24 | 1 payment
|
| Allergan | Lo Loestrin Fe | $21 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Sumitomo Pharma America, Inc. · A Phase 3 Singlearm Openlabel Study To Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 To 50 Years of Age and at Risk for Pregnancy · 2024 | Their institution | $77,838 |
| Sumitomo Pharma America, Inc. · A Phase 3, Single-Arm, Open-Label Study To Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 To 50 Years of Age and at Risk for Pregnancy · 2025 | Their institution | $29,169 |
| Abbott Laboratories · Alinity M Hr Hpv Self-Collect Study (Ce) Protocol for Specimen Collection From Subjects Undergoing Routine Cervical Cancer Screening · 2023 | Their institution | $25,027 |
| Abbott Laboratories · Alinity M Hr Hpv Specimen Collection Study From Women Referred To Colposcopy · 2022 | Their institution | $19,199 |
| Sumitomo Pharma America, Inc. · Serene · 2023 | Their institution | $6,941 |
| Sumitomo Pharma America, Inc. · A Phase 3, Single-Arm, Open-Label Study To Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 To 50 Years of Age and at Risk for Pregnancy · 2023 | Their institution | $2,310 |
Professional record
- NPI
- 1306942909
- Licence
- CA A061790
- Trained
- University of California, Geffen School of Medicine, 1994 · 32 years ago
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A617900
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 1045 W Redondo Beach Blvd, #500, Gardena, CA, 90247
- NPI first listed
- 2006-09-15
- NPI last updated
- 2008-01-31
This is when the NPI record was last certified, not a medical board exam.